The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 17, 2018
Filed:
Mar. 02, 2017
Applicant:
Thomas Helledays Stiftelse for Medicinsk Forskning, Stocksund, SE;
Inventors:
Martin Scobie, Uppsala, SE;
Thomas Helleday, Stocksund, SE;
Tobias Koolmeister, Stockholm, SE;
Sylvain Jacques, Lyons, FR;
Matthieu Desroses, Knivsta, SE;
Marie-Caroline Jacques-Cordonnier, Lyons, FR;
Assignee:
THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING, Stocksund, SE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/04 (2006.01); C07D 417/12 (2006.01); C07D 401/04 (2006.01); C07D 239/48 (2006.01); C07D 405/12 (2006.01); C07D 405/14 (2006.01); C07D 405/04 (2006.01); C07B 59/00 (2006.01); A61K 31/505 (2006.01); C07D 403/12 (2006.01); A61K 31/506 (2006.01); C07D 403/14 (2006.01); C07D 409/04 (2006.01); C07D 403/04 (2006.01); C07D 453/02 (2006.01); A61K 45/06 (2006.01); A61K 31/5377 (2006.01); C07D 401/14 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 31/505 (2013.01); A61K 31/506 (2013.01); A61K 31/5377 (2013.01); A61K 45/06 (2013.01); C07B 59/002 (2013.01); C07D 239/48 (2013.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 403/04 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/04 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/04 (2013.01); C07D 417/12 (2013.01); C07D 453/02 (2013.01); C07B 2200/05 (2013.01);
Abstract
A compound of formula I, or a pharmaceutically-acceptable salt thereof. The compound is useful in the treatment of cancer or other diseases that may benefit from inhibition of MTH1.